Model diagrams for analysis comparing pola-R-CHP vs R-CHOP in untreated DLBCL. (A) For all states, patients remain in the same state if they are not transitioning to another state in the model. ∗Patients are considered to enter remission if they have achieved a complete remission at the end of initial therapy. Patients with any residual disease after the completion of initial therapy are considered primary refractory and proceed to salvage chemoimmunotherapy (salvage chemo) along with patients who progress during or after initial therapy. Patients with RR DLBCL receive salvage chemo; if they respond, they proceed to auto-SCT. If they do not respond, they proceed with third-line CAR T. ^†Patients who progress after third-line CAR-T therapy are considered to have a poor prognosis, low quality of life, and high costs. (B) Model diagram for analysis comparing pola-R-CHP vs R-CHOP in untreated DLBCL when CAR-T therapy is used in the second-line setting for early progression/primary nonresponse. In this model, patients who are primary nonresponders after initial therapy or progress within 12 months of initial therapy receive CAR-T therapy (axi-cel) in the second-line setting using the ZUMA-7 data. Patients who are late progressors (>12 months) receive salvage chemo as a bridge to auto-SCT and can receive third-line CAR-T therapy if they do not respond or relapse. Patients who receive second-line CAR-T therapy and progress can receive salvage chemo, with low overall response rates.